A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection
The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) vaccine tablet VXA-CoV2-3.3 compared to a currently recommended vaccine for the prevention of symptomatic Coronavirus Disease 2019 (COVID-19).
In order to represent a more recently circulating SARS-CoV-2 variant, the main study endpoints will now evaluate the VXA-CoV2-3.3 (KP.2 strain) vaccine, and not the VXA-CoV2-3.1 (XBB.1.5 strain) vaccine.
Protocol Amendment History
4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-11-01; most recent amendment 2026-06-22.
Status change: Recruiting → Active, Not Recruiting2025-10-20
Status change: Active, Not Recruiting → Recruiting2025-06-03
Status change: Recruiting → Active, Not Recruiting2025-04-15